title: Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
authors: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
authors: Senthilkumar
authors: S
authors: Damodaran
authors: Tanya
authors: T
authors: Bellavia
authors: Sheila N J
authors: SN
authors: Sait
authors: Eunice S
authors: ES
authors: Wang
authors: Meir
authors: M
authors: Wetzler
authors: Nikhil I
authors: NI
authors: Khushalani
mesh_terms: D059786:Abnormal Karyotype; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000069287:Capecitabine; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D016629:Esophagectomy; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D000077150:Oxaliplatin; D011878:Radiotherapy; D014178:Translocation, Genetic
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil